UROGEN PHARMA LTD (URGN) Forecast, Price Target & Analyst Ratings
NASDAQ:URGN • IL0011407140
19.95 USD
+1.13 (+6%)
Last: Mar 4, 2026, 01:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for UROGEN PHARMA LTD (URGN).
Forecast Snapshot
Consensus Price Target
$35.96
+ 80.23% Upside
Next Earnings Forecast
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$0.53
Revenue Estimate46.2M
ChartMill Buy Consensus
84.29%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$35.96
Upside
+ 80.23%
From current price of $19.95 to mean target of $35.96, Based on 14 analyst forecasts
Low
$16.16
Median
$34.68
High
$57.75
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
14 analysts have analysed URGN and the average price target is 35.96 USD. This implies a price increase of 80.23% is expected in the next year compared to the current price of 19.95.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.29%
URGN was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about URGN.
In the previous month the buy percentage consensus was at a similar level.
URGN was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-23 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-03 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
| 2025-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-08-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-07-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-07 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-06-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-06-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-06-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-23 | Guggenheim | Maintains | Buy -> Buy |
| 2025-05-22 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-22 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-29 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-04-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$0.53
Revenue Estimate46.2M
Revenue Q2Q128.10%
EPS Q2Q42.66%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
-0.53%
Revenue (3 Months)
-3.69%
EPS (1 Month)
-0.75%
EPS (3 Months)
-4.15%
Next Earnings Summary
URGN is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.53 USD and the consensus revenue estimate is 46.20M USD.
The next earnings revenue estimate has been revised downward by 3.69% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 64.36M 33.97% | 82.713M 28.52% | 90.398M 9.29% | 114.11M 26.23% | 240.84M 111.06% | 396.88M 64.79% | 526.91M 32.76% | 721.88M 37.00% | 947.68M 31.28% | 1.437B 51.63% | 1.565B 8.91% | 1.696B 8.37% | |
| EBITDA YoY % growth | -78.12M 14.59% | -64.734M 17.14% | -96.453M -49.00% | -119.489M -23.88% | -39.798M 66.69% | 40.336M 201.35% | 108.39M 168.72% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -79.04M 14.36% | -65.536M 17.09% | -96.782M -47.68% | -124.957M -29.11% | -34.959M 72.02% | 72.719M 308.01% | 261.1M 259.05% | 418.72M 60.37% | 621.67M 48.47% | 1.13B 81.77% | 1.229B 8.76% | 1.335B 8.62% | |
| Operating Margin | -122.81% | -79.23% | -107.06% | -109.51% | -14.52% | 18.32% | 49.55% | 58.00% | 65.60% | 78.64% | 78.53% | 78.71% | |
| EPS YoY % growth | -4.78 3.57% | -3.73 22.02% | -3.23 13.40% | -3.24 0.93% | -1.20 62.62% | 0.77 164.29% | 3.00 290.45% | 4.74 57.81% | 6.35 33.99% | 9.09 43.21% | 9.34 2.75% | 9.83 5.24% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 42.66% | -0.39 62.95% | -0.22 68.32% | -0.05 91.18% |
| Revenue Q2Q % growth | 46.2M 128.10% | 54.321M 124.33% | 65.163M 137.11% | 73.969M 95.48% |
| EBITDA Q2Q % growth | -19.054M 48.28% | -16.534M 59.96% | -5.042M 81.43% | N/A |
| EBIT Q2Q % growth | -13.714M 62.85% | -10.035M 75.79% | -3.007M 89.02% | 3.171M 118.60% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
43.23%
EPS Next 5 Year
31.85%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
66.52%
Revenue Next 5 Year
52.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
34.43%
EBIT Next 5 Year
33.26%
UROGEN PHARMA LTD / URGN Forecast FAQ
Can you provide the average price target for UROGEN PHARMA LTD stock?
14 analysts have analysed URGN and the average price target is 35.96 USD. This implies a price increase of 80.23% is expected in the next year compared to the current price of 19.95.
Can you provide the upcoming earnings date for UROGEN PHARMA LTD?
UROGEN PHARMA LTD (URGN) will report earnings on 2026-05-11.
Can you provide the consensus estimates for UROGEN PHARMA LTD next earnings?
The consensus EPS estimate for the next earnings of UROGEN PHARMA LTD (URGN) is -0.53 USD and the consensus revenue estimate is 46.20M USD.
What is the consensus rating for UROGEN PHARMA LTD (URGN) stock?
The consensus rating for UROGEN PHARMA LTD (URGN) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.